Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M. Guckenberger M, et al. Among authors: flentje m. Radiother Oncol. 2013 Oct;109(1):13-20. doi: 10.1016/j.radonc.2013.09.005. Epub 2013 Oct 30. Radiother Oncol. 2013. PMID: 24183066
Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.
Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F. Guckenberger M, et al. Among authors: flentje m. Radiother Oncol. 2016 Mar;118(3):485-91. doi: 10.1016/j.radonc.2015.09.008. Epub 2015 Sep 15. Radiother Oncol. 2016. PMID: 26385265
Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases.
Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Flentje M, Ganswindt U, Hass P, Henkenberens C, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Schmitt V, Semrau S, Sterzing F, Streblow J, Wendt TG, Wittig A, Guckenberger M. Klement RJ, et al. Among authors: flentje m. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):841-9. doi: 10.1016/j.ijrobp.2015.12.004. Epub 2015 Dec 15. Int J Radiat Oncol Biol Phys. 2016. PMID: 26972657
Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy.
Klement RJ, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Eich HC, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl KH, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Guckenberger M. Klement RJ, et al. Among authors: flentje m. Radiother Oncol. 2018 May;127(2):246-252. doi: 10.1016/j.radonc.2018.02.016. Epub 2018 Mar 3. Radiother Oncol. 2018. PMID: 29510865
Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.
Klement RJ, Sonke JJ, Allgäuer M, Andratschke N, Appold S, Belderbos J, Belka C, Dieckmann K, Eich HT, Flentje M, Grills I, Eble M, Hope A, Grosu AL, Semrau S, Sweeney RA, Hörner-Rieber J, Werner-Wasik M, Engenhart-Cabillic R, Ye H, Guckenberger M. Klement RJ, et al. Among authors: flentje m. Radiother Oncol. 2020 Jan;142:210-216. doi: 10.1016/j.radonc.2019.07.008. Epub 2019 Aug 17. Radiother Oncol. 2020. PMID: 31431371
Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.
Hartrampf PE, Hänscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, Sweeney RA, Buck AK, Polat B, Lapa C. Hartrampf PE, et al. Among authors: flentje m. Clin Transl Radiat Oncol. 2020 Mar 5;22:29-32. doi: 10.1016/j.ctro.2020.03.002. eCollection 2020 May. Clin Transl Radiat Oncol. 2020. PMID: 32195377 Free PMC article.
Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial.
Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, Hohenberger W, Arnold D, Hofheinz RD, Ghadimi M, Ströbel P, Staib L, Grabenbauer GG, Folprecht G, Kirste S, Uter W, Gall C, Rödel C, Polat B; of the German Rectal Cancer Study Group. Kosmala R, et al. Among authors: flentje m. Eur J Cancer. 2021 Feb;144:281-290. doi: 10.1016/j.ejca.2020.11.029. Epub 2020 Dec 28. Eur J Cancer. 2021. PMID: 33383348 Clinical Trial.
451 results